Search

Your search keyword '"Huang, Shixia"' showing total 146 results

Search Constraints

Start Over You searched for: Author "Huang, Shixia" Remove constraint Author: "Huang, Shixia" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
146 results on '"Huang, Shixia"'

Search Results

1. The IFITM5 mutation in osteogenesis imperfecta type V is associated with an ERK/SOX9-dependent osteoprogenitor differentiation defect

4. Inhibition of GATA2 in prostate cancer by a clinically available small molecule.

7. Supplementary Figure S1 from Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer

8. Data from Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer

9. Supplementary Tables S1-8 from Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer

10. Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer

11. The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer

13. SOD1 is a synthetic lethal target in PPM1D-mutant leukemia cells

14. Author Response: SOD1 is a synthetic lethal target in PPM1D-mutant leukemia cells

15. Targeting TGF-[beta] for treatment of osteogenesis imperfecta

18. Caspase-2 is essential for proliferation and self-renewal of nucleophosmin-mutated acute myeloid leukemia.

19. Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice

20. Data from Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer

21. Figures S1-7 from Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer

24. Data from Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes

25. Supplementary File 5 from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

26. Supplementary File 1 from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

27. Supplementary File 2 from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

28. Extended Methods from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

29. Supplementary File 3 from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

30. Supplementary Figures from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

31. Figure S8 from Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes

32. Supplementary Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer

33. Supplementary tables 1 and 2 from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

34. Data from A Wnt-Independent LGR4–EGFR Signaling Axis in Cancer Metastasis

35. Supplementary Data from A Wnt-Independent LGR4–EGFR Signaling Axis in Cancer Metastasis

36. Data from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

37. Supplementary File 4 from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

42. Molecular mechanisms of TWIST1‐regulated transcription in EMT and cancer metastasis.

44. Selective CDK7 Inhibition Has Dual Activity in Treatment Resistant Estrogen Receptor Positive Breast Cancer

45. 3232 – TARGETING SOD1 INDUCES SYNTHETIC LETHAL KILLING OF PPM1D-MUTANT LEUKEMIA CELLS

48. LncRNA PVT-1 promotes osteosarcoma cancer stem-like properties through direct interaction with TRIM28 and TSC2 ubiquitination

49. High-throughput profiling of histone post-translational modifications and chromatin modifying proteins by reverse phase protein array

50. Targeting TGF-β for treatment of osteogenesis imperfecta

Catalog

Books, media, physical & digital resources